Kimitoshi Nakamura

Kimitoshi Nakamura

Auto-generated profile, based on publicly available information

Kimitoshi Nakamura

Department of Pediatrics, Kumamoto University Hospital, Kumamoto, Japan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2011 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
JKJun Kido
Jun Kido
KNKimitoshi Nakamura
Kimitoshi Nakamura
HMHiroshi Mitsubuchi
Hiroshi Mitsubuchi
TOToshihiro Ohura
Toshihiro Ohura
MTMasaki Takayanagi
Masaki Takayanagi
FEFumio Endo
Fumio Endo

1 November 2017 in Molecular Genetics and Metabolism
Verified
Journal Article
Open access
AMAtul B Mehta
Atul B Mehta
NBNadia Belmatoug
Nadia Belmatoug
BBBruno Bembi
Bruno Bembi
Patrick B. DeeganPatrick B. Deegan
Patrick B. Deegan
DEDeborah Elstein
Deborah Elstein
DHDerralynn Hughes
Derralynn Hughes
Gaucher disease (GD) is a rare hereditary disorder caused by a deficiency of the lysosomal enzyme β-glucocerebrosidase. Diagnosis is challenging owing to a wide variability in clinical manifestations and severity of symptoms. Many patients may experience marked delays in obtaining a definitive diagnosis. The two surveys reported herein aimed to explore the patient journey to diagnosis of GD from the perspectives of Gaucher expert physicians and patients. Findings from the surveys revealed that many patients experienced diagnostic delays and misdiagnoses, with nearly 1 in 6 patients stating that they were not diagnosed with GD for 7years or more after first consulting a doctor. Physicians and patients both reported multiple referrals to different specialties before a diagnosis of GD was obtained, with primary care, haematology/haematology-oncology and paediatrics the main specialties to which patients first presented. Splenomegaly, thrombocytopenia, anaemia and bone pain were reported as the most common medical problems at first presentation in both surveys. These findings support a clear need for straightforward and easy-to-follow guidance designed to assist non-specialists to identify earlier patients who are at risk of GD.

Verified
Journal Article
Open access
PDF file
TSTakaaki Sawada
Takaaki Sawada
JKJun-ichi Kido
Jun-ichi Kido
KNKimitoshi Nakamura
Kimitoshi Nakamura
Glycogen storage disease type II (also known as Pompe disease (PD)) is an autosomal recessive disorder caused by defects in α-glucosidase (AαGlu), resulting in lysosomal glycogen accumulation in skeletal and heart muscles. Accumulation and tissue damage rates depend on residual enzyme activity. Enzyme replacement therapy (ERT) should be started before symptoms are apparent in order to achieve optimal outcomes. Early initiation of ERT in infantile-onset PD improves survival, reduces the need for ventilation, results in earlier independent walking, and enhances patient quality of life. Newborn screening (NBS) is the optimal approach for early diagnosis and treatment of PD. In NBS for PD, measurement of AαGlu enzyme activity in dried blood spots (DBSs) is conducted using fluorometry, tandem mass spectrometry, or digital microfluidic fluorometry. The presence of pseudodeficiency alleles, which are frequent in Asian populations, interferes with NBS for PD, and current NBS systems cannot discriminate between pseudodeficiency and cases with PD or potential PD. The combination of GAA gene analysis with NBS is essential for definitive diagnoses of PD. In this review, we introduce our experiences and discuss NBS programs for PD implemented in various countries.

10 February 2011 in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
Verified
Journal Article
Closed access
PDF file
KNKimitoshi Nakamura
Kimitoshi Nakamura
KHKiyoko Hattori
Kiyoko Hattori
FEFumio Endo
Fumio Endo

Verified
Journal Article
Open access
PDF file
Roberto GiuglianiRoberto Giugliani
Roberto Giugliani
AMAna Maria Martins
Ana Maria Martins
TOTorayuki Okuyama
Torayuki Okuyama
YEYoshikastu Eto
Yoshikastu Eto
NSNorio Sakai
Norio Sakai
YSYuji Sato
Yuji Sato
Enzyme replacement therapy (ERT) improves somatic manifestations in mucopolysaccharidoses (MPS). However, because intravenously administered enzymes cannot cross the blood–brain barrier (BBB), ERT is ineffective against the progressive neurodegeneration and resultant severe central nervous system (CNS) symptoms observed in patients with neuronopathic MPS. Attempts to surmount this problem have been made with intrathecal and intracerebroventricular ERT in order to achieve CNS effects, but the burdens on patients are inimical to long-term administrations. However, since pabinafusp alfa, a human iduronate-2-sulfatase fused with a BBB-crossing anti-transferrin receptor antibody, showed both central and peripheral efficacy in a mouse model, subsequent clinical trials in a total of 62 patients with MPS-II (Hunter syndrome) in Japan and Brazil substantiated this dual efficacy and provided an acceptable safety profile. To date, pabinafusp alfa is the only approved intravenous ERT that is effective against both the somatic and CNS symptoms of patients with MPS-II. This article summarizes the previously obtained preclinical and clinical evidence related to the use of this drug, presents latest data, and discusses the preclinical, translational, and clinical challenges of evaluating, ameliorating, and preventing neurodegeneration in patients with MPS-II.

26 September 2016 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
RSRieko Sakamoto
Rieko Sakamoto
KNKimitoshi Nakamura
Kimitoshi Nakamura
JKJun Kido
Jun Kido
SMShiro Matsumoto
Shiro Matsumoto
HMHiroshi Mitsubuchi
Hiroshi Mitsubuchi
FEFumio Endo
Fumio Endo